Cefotax 500mg IM/IV Injection — Cefotaxime 500mg by Beximco Pharmaceuticals

Cefotax 500mg IM/IV Injection — Cefotaxime 500mg | Beximco Pharmaceuticals

Overview

Cefotax 500mg contains Cefotaxime Sodium 500mg — a third-generation cephalosporin antibiotic providing broad-spectrum bactericidal activity against a wide range of Gram-positive and Gram-negative pathogens. The 500mg strength bridges the gap between the paediatric 250mg dose and the standard adult 1g dose, and is used for moderate infections in adults and weight-appropriate dosing in children. Cefotaxime is distinguished by its excellent tissue and CSF penetration, making it one of the preferred agents for bacterial meningitis, and its strong Gram-negative coverage, making it valuable for pneumonia, complicated UTIs, intra-abdominal infections, and diabetic foot infections with systemic or Gram-negative involvement.

Mechanism of Action

Cefotaxime inhibits bacterial cell wall synthesis by binding penicillin-binding proteins (PBPs) and preventing peptidoglycan cross-linking — resulting in osmotic lysis and bacterial death. Enhanced stability to beta-lactamases compared to first and second generation cephalosporins provides improved Gram-negative activity. Not active against MRSA, Enterococcus, Pseudomonas aeruginosa, or ESBL-producing organisms.

Indications

• Pneumonia — community-acquired and hospital-acquired (covers S. pneumoniae, H. influenzae, Enterobacteriaceae)
• Bacterial Meningitis — first-line for Gram-negative meningitis; excellent CSF penetration
• Septicaemia / Bacteraemia — systemic bacterial infection
• Complicated UTI and Pyelonephritis — Gram-negative bacteria including E. coli and Klebsiella
• Intra-abdominal infections — peritonitis, cholangitis (combined with metronidazole)
• Diabetic foot infections — moderate-severe with Gram-negative or systemic involvement
• Gynaecological infections — PID, post-operative infections
• Paediatric infections — neonatal sepsis, childhood meningitis and severe infections

Dosage and Administration

Reconstitute with sterile water for injection per hospital protocol. IV: slow injection over 3–5 minutes or infusion over 20–60 minutes. IM: may use lidocaine as diluent to reduce injection pain. Dose reduce in renal impairment (CrCl <20 mL/min).

Critical Notes for Diabetic Patients

• Severe diabetic infections (septicaemia, severe foot infections, complicated pneumonia) often require parenteral cefotaxime — oral antibiotics are inadequate when systemic spread or Gram-negative organisms are involved
• Infection-induced hyperglycaemia is profound in sepsis — intensive blood glucose monitoring and IV insulin infusion are standard during hospitalisation with IV antibiotics
• Always check eGFR — diabetic nephropathy is common; dose reduction is required in significant renal impairment
• Wound culture and sensitivity testing before initiating antibiotics guides appropriate spectrum selection — particularly important in diabetic foot infections where polymicrobial flora is common

Side Effects

Injection site reactions (pain, phlebitis), GI symptoms (diarrhoea, nausea), hypersensitivity reactions (rash, urticaria — uncommon), anaphylaxis (rare; ~1–2% cross-reactivity with penicillin allergy), C. difficile colitis (uncommon), elevated LFTs (transient, uncommon), neurotoxicity with high doses in renal failure (rare).

Contraindications

• Known hypersensitivity to cefotaxime or cephalosporins
• Severe immediate hypersensitivity to penicillins (use with caution — low but real cross-reactivity)

Storage

Store unreconstituted vials below 25°C, protected from light. Use reconstituted solution within 6 hours at room temperature or 24 hours refrigerated. Keep out of reach of children.

Medical Disclaimer: This information is for educational purposes only. Injectable antibiotics must be administered by trained healthcare personnel in clinical settings. Diabetic patients with signs of severe infection require emergency medical evaluation. Prescription required.